Dispensación de antimicóticos vaginales en la oficina de farmacia

  1. MARTÍNEZ IGLESIAS, Laura 1
  2. ALDASORO MARTÍN, Pilar 1
  1. 1 Farmacia Ana María Díaz Pérez, Oviedo
Journal:
Farmajournal

ISSN: 2445-1355

Year of publication: 2017

Volume: 2

Issue: 2

Pages: 81-93

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Farmajournal

Abstract

It is considered that changes in the stability of the vaginal microbiota are considered to increase susceptibility to infections such as vaginal Candidiasis caused by Candida fungus, sensitive to oral and topical antifungals.Objectives: Being able to know the prevalence of vaginal Candidiasis, to study the most dispensed antifungal drugs in Pharmacy, as well as the promotion of the use of prevention methods.Materials and methods: Demoscopic study of the prevalence of vaginal Candidiasis in a pharmacy during the period from September 2015 to February 2016. Data was collected with the help of a survey and analyzed using the Office-Excel system and SigmaStat 3.5 software.Results and Discussion: According to the data collected, most respondents have suffered more than 3 previous infections.The ingestion of antibiotics affects the vaginal flora favoring the appearance of infections. Older women are more likely to get vaginal antifungals without a prescription.Conclusion: The pharmacist must ensure the knowledge of adequate compliance with antifungal treatment; in specific cases it is mandatory to refer to the doctor to avoid the appearance of resistance to the treatment. It should also advise the use of suitable products and probiotics to avoid future relapses. 

Bibliographic References

  • Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG. 2015;122(6):785-94.
  • Eloe-Fadrosh EA, Rasko DA. The human microbiome: from symbiosis to pathogenesis. Annu Rev Med. 2013; 64: 145–63.
  • Greenwood PE, Nikulin MS. A guide to chi-squared testing. Wiley, New York; 1996.
  • Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013; 209: 505–23.
  • Leitsch D. Recent Advances in the Trichomonas vaginalis Field. F1000Res. 2016 Feb 11;5. pii: F1000 Faculty Rev-162.
  • Lorenzo P, Moreno A, Leza JC, Lizasoain I, Moro MA. Velázquez, Farmacología Básica y Clínica. 17ª Edición. Buenos Aires, Madrid: Médica Panamericana; 2004.
  • Martín R, Soberón N, Vázquez F, Suárez JE. La microbiota vaginal: composición, papel protector, patología asociada y perspectivas terapéuticas. Enfermedades Infecciosas y Microbiología Clínica. 2008; 26(3):160-167.
  • O-Prasertsawat P, Bourlert A. Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis. Sex Transm Dis. 1995 Jul-Aug; 22(4):228-30.
  • Recalde JM. Vulvovaginitis por Candida: tratamiento. Bol. Ter. And. [Internet]. 2003 [18/8/2016]; 19(5): 17-20. Disponible en: http://www.cadime.es/docs/bta/CADIME_BTA2003_19_5.pdf
  • Rosa MI, Silva BR, Pires PS, Silva FR, Silva NC, Silva FR, et al. Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013 Apr; 167(2): 132-6.
  • Veraldi, S; Milani, R. Topical Fenticonazole in Dermatology and Gynaecology. Drugs. 2008; 68: 2183.
  • Waitz, A; Moss, EL; Weinstein, MJ. Chemotherapeutic evaluation of clotrimazole (Bay b 5097, I (o-chioro-c-o-diphenylbenzyl] imidazole). Applied Microbiology. 1971; 22: 891.
  • Xu J, Schwartz K, Bartoces M, Monsur J, Severson RK, Sobel JD. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. Journal of the American Board of Family Medicine. 2008; 21(4):261-8.
  • Zardaín-Tamargo E. Canddidiasis Vaginal: Indicación farmacéutica. Farmas. 2013; 22(3)
Data source: Dialnet